SCHEMBL1499595

SCHEMBL1499595

CC(C)CCNC(=O)c1cccc(Nc2ccc(/C=C/c3ccncc3)cc2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.47
RXFP1 Q9HBX9 1/20 0.47
SMN1; SMN2 Q16637 3/20 0.44
RAB9A P51151 3/20 0.44
LMNA P02545 2/20 0.44
NPC1 O15118 2/20 0.44
POLB P06746 1/20 0.44
MAPT P10636 1/20 0.44
GFER P55789 1/20 0.44
NAMPT P43490 4/20 0.44
F3 P13726 1/20 0.43
MEN1 O00255 1/20 0.43
AGTR1 P30556 1/20 0.43
KMT2A Q03164 1/20 0.43
ROCK2 O75116 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP3A5 P20815 1/20 0.42
BRAF P15056 1/20 0.42
PSMB5 P28074 1/20 0.41
EPHX2 P34913 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1499597 1.00 TP53 (0.47) TP53RXFP1SMN1; SMN2RAB9ALMNA
SCHEMBL1499344 0.94 TP53 (0.47) TP53RXFP1SMN1; SMN2RAB9ALMNA
SCHEMBL1499347 0.94 TP53 (0.47) TP53RXFP1SMN1; SMN2RAB9ALMNA
SCHEMBL29973395 0.91 SMN1; SMN2 (0.46) TP53RXFP1SMN1; SMN2RAB9ALMNA
SCHEMBL1499338 0.91 SMN1; SMN2 (0.46) TP53RXFP1SMN1; SMN2RAB9ALMNA
SCHEMBL1499342 0.91 SMN1; SMN2 (0.46) TP53RXFP1SMN1; SMN2RAB9ALMNA
SCHEMBL21617137 0.90 NAMPT (0.50) TP53RXFP1SMN1; SMN2RAB9ALMNA
SCHEMBL1499725 0.88 TP53 (0.47) TP53RXFP1SMN1; SMN2RAB9ALMNA
SCHEMBL29973692 0.88 TP53 (0.47) TP53RXFP1SMN1; SMN2RAB9ALMNA
SCHEMBL1499728 0.88 TP53 (0.47) TP53RXFP1SMN1; SMN2RAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104130242-B Chemical molecules inhibiting the splicing mechanism for the treatment of diseases caused by splicing abnormalities 国家科研中心 2016-10-05 CN claimed
CN-104130242-A Chemical molecules inhibiting the splicing mechanism for the treatment of diseases caused by splicing abnormalities CENTRE NAT RECH SCIENT 2014-11-05 CN claimed
US-8604063-B2 Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies CENTRE NATIONAL DE RECHERCHE SCIENTIFIQUE (FR) 2013-12-10 US claimed
JP-2011509280-A 2011-03-24 JP claimed
US-20110053975-A1 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) 2011-03-03 US claimed
CN-101965341-A Chemical molecules inhibiting the splicing mechanism for the treatment of diseases caused by splicing abnormalities CT NAT RECHSEARCH SCIENT 2011-02-02 CN claimed
EP-2235000-A2 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES Centre National de la Recherche Scientifique (CNRS) (FR) 2010-10-06 EP claimed
WO-2009087238-A9 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2010-02-25 WO claimed
WO-2009087238-A2 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2009-07-16 WO claimed
EP-3536691-B1 CHEMICAL MOLECULES THAT INHIBIT THE SPLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NAT RECH SCIENT (FR) 2022-10-05 EP disclosed
EP-2235000-B1 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NAT RECH SCIENT (FR) 2020-06-17 EP disclosed
EP-2235000-B1 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NAT RECH SCIENT (FR) 2020-06-17 EP disclosed
US-10654813-B2 Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2020-05-19 US disclosed
US-10654813-B2 Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2020-05-19 US disclosed
US-20110053975-A1 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) 2011-03-03 US disclosed
US-20110053975-A1 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) 2011-03-03 US disclosed
CN-101965341-A Chemical molecules inhibiting the splicing mechanism for the treatment of diseases caused by splicing abnormalities CT NAT RECHSEARCH SCIENT 2011-02-02 CN disclosed
EP-2235000-A2 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES Centre National de la Recherche Scientifique (CNRS) (FR) 2010-10-06 EP disclosed
WO-2009087238-A9 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2010-02-25 WO disclosed
WO-2009087238-A2 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2009-07-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10654813-B2 Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies RBM17, RBM22, PRPF40A TP53 3059/4885RXFP1 3544/4885SMN1; SMN2 13/4885
US-20110053975-A1 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES RBM17, SF3B5, SF3B1 TP53 3942/4885RXFP1 2144/4885SMN1; SMN2 32/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.